WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera”...
WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera”...
WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life...
– Final stage of technical evaluation near completion in Comera’s research collaboration with Regeneron, a...
WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life...
WOBURN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life...
Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity...
– Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading...
WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life...
WOBURN, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life...
– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over...
– Significant progress in Comera’s ongoing research collaboration with Regeneron, a leading U.S. biotechnology...
WOBURN, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA...
– Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for...
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.